Dermatophagoides Farinae

For Sublingual Immunotherapy (SLIT), the standard adult dose for Dermatophagoides Farinae (often combined with D. pteronyssinus in products like ODACTRA) is typically one tablet (12 SQ-HDM) taken once daily. There is no 'build-up' phase required for the sublingual tablet form; the maintenance dose is started immediately.

For Subcutaneous Immunotherapy (SCIT), the dosage is highly individualized. It follows a two-phase schedule:

1. 1Build-up Phase: Injections are given 1–3 times per week, starting with a very low concentration (e.g., 0.05 mL of a 1:10,000 dilution). The dose is gradually increased over 3 to 6 months until the maintenance dose is reached.
2. 2Maintenance Phase: Once the effective dose is reached (e.g., 0.5 mL of a 1:100 or 1:10 concentration), the frequency of injections is reduced to once every 2 to 4 weeks.

• Sublingual Tablets: In the United States, ODACTRA is FDA-approved for use in adolescents and adults aged 12 through 65 years. It is NOT currently approved for children under the age of 12.
• Subcutaneous Injections: SCIT is frequently used in children as young as 5 years old, provided the child is cooperative and the benefits outweigh the risks of systemic reactions. Dosing follows the same build-up and maintenance logic as adults but may be adjusted based on the child's sensitivity.

Renal Impairment

No dosage adjustments are required for patients with renal (kidney) impairment, as the proteins are not cleared by the kidneys in a way that would lead to systemic accumulation.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic (liver) impairment.

Elderly Patients

Clinical trials for SLIT included patients up to age 65. For patients over 65, the efficacy and safety have not been extensively studied. Healthcare providers must assess the patient's overall health, particularly cardiovascular status, as elderly patients may be less able to tolerate the epinephrine required to treat a rare systemic reaction.

For Sublingual Tablets:

1. 1Administration: Take the tablet out of the blister pack with dry hands. Place it immediately under the tongue.
2. 2Dissolution: Allow the tablet to dissolve completely (usually takes a few seconds). Do not swallow for at least one minute.
3. 3Food and Drink: Do not eat or drink for at least 5 minutes after the tablet has dissolved to ensure maximum contact with the oral mucosa.
4. 4First Dose: The first dose MUST be taken in a healthcare setting under the supervision of a physician experienced in treating allergies. The patient must be observed for at least 30 minutes for signs of a severe systemic reaction.

For Subcutaneous Injections:

• These must only be administered by a healthcare professional in a facility equipped with emergency supplies (epinephrine, oxygen, IV fluids) to treat anaphylaxis. Patients must wait in the clinic for 30 minutes post-injection.

• SLIT: If a daily dose is missed, do not take a double dose. Resume the next day at the regular time. If more than 7 days of doses are missed, consult your doctor before restarting, as a dose reduction may be necessary to ensure safety.
• SCIT: If an injection is missed, contact your allergist. Depending on how long it has been since the last shot, the doctor may need to reduce the dose for the next injection to avoid a reaction.

An overdose of Dermatophagoides Farinae (taking more than the prescribed amount) significantly increases the risk of severe local and systemic allergic reactions, including anaphylaxis. Signs include swelling of the tongue, throat tightness, difficulty breathing, and a drop in blood pressure. In case of suspected overdose, seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop treatment without medical guidance, as this can affect the efficacy and safety of the immunotherapy.

Because Dermatophagoides Farinae is an allergen, local allergic reactions are expected as the body's immune system interacts with the extract. For Sublingual (SLIT) users, common side effects include:

• Throat Irritation: A 'scratchy' or 'itchy' feeling in the back of the throat. This typically occurs within minutes of administration and lasts for 30 to 60 minutes.
• Oral Pruritus: Itching of the mouth or tongue.
• Ear Pruritus: Itching inside the ears, which is a referred sensation from the throat.
• Mouth Edema: Mild swelling of the tissues inside the mouth or under the tongue.

For Subcutaneous (SCIT) users:

• Injection Site Reactions: Redness, itching, and swelling (wheal) at the site of the injection. These are usually mild and resolve within 24 hours.

• Nausea and Abdominal Pain: Some patients may experience mild stomach upset if they swallow the extract too quickly.
• Urticaria (Hives): Itchy red bumps appearing on various parts of the body, not just the site of administration.
• Cough and Sneezing: Mild respiratory irritation shortly after taking the dose.
• Oral Paresthesia: A tingling or 'pins and needles' sensation in the mouth.

• Eosinophilic Esophagitis (EoE): A chronic immune system disease where white blood cells (eosinophils) build up in the lining of the esophagus. Symptoms include difficulty swallowing or chest pain.
• Severe Tongue or Throat Swelling: Swelling that makes it difficult to speak or swallow.
• Laryngeal Edema: Swelling of the voice box (larynx), which is a medical emergency.

> Warning: Stop taking Dermatophagoides Farinae and call your doctor or emergency services immediately if you experience any of these signs of Anaphylaxis:

1. 1Difficulty Breathing or Wheezing: Sudden onset of shortness of breath or a whistling sound when breathing.
2. 2Throat Tightness: A feeling that the airway is closing or a sudden change in voice (hoarseness).
3. 3Dizziness or Fainting: A rapid drop in blood pressure (hypotension) leading to lightheadedness or loss of consciousness.
4. 4Rapid or Weak Pulse: Cardiovascular distress associated with a systemic allergic reaction.
5. 5Generalized Hives and Swelling: A widespread rash accompanied by swelling of the face, lips, or eyes.

There are no known long-term 'toxic' effects of Dermatophagoides Farinae extracts. The primary long-term consideration is the successful modulation of the immune system. However, patients should be monitored for the development of Eosinophilic Esophagitis (EoE) over months or years of sublingual treatment. If a patient develops persistent heart burn or difficulty swallowing, the treatment may need to be permanently discontinued.

Sublingual Dermatophagoides Farinae products (like ODACTRA) carry an FDA Black Box Warning regarding the risk of severe allergic reactions.

• Anaphylaxis: Treatment can cause life-threatening allergic reactions.
• Observation: The first dose must be administered under medical supervision.
• Epinephrine: Patients must be prescribed an auto-injectable epinephrine (e.g., EpiPen) and be trained on how to use it while on this medication.
• Contraindications: Do not use in patients with severe, unstable, or uncontrolled asthma, or those with a history of severe systemic or local reactions to sublingual immunotherapy.

Report any unusual symptoms, especially those affecting your breathing or digestion, to your healthcare provider promptly.

Dermatophagoides Farinae extract is a potent biological substance. It is not a symptom-reliever (like an antihistamine) but a disease-modifying therapy. Patients must understand that they are being intentionally exposed to a substance they are allergic to. Safety depends on strict adherence to the prescribed dose and monitoring for systemic symptoms.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

• Dermatophagoides Farinae immunotherapy can cause life-threatening allergic reactions such as anaphylaxis.
• Do not administer to patients with severe, unstable, or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Prescribe auto-injectable epinephrine to all patients and instruct them on its proper use. Patients should be instructed to seek immediate medical care upon use of epinephrine.
• Dermatophagoides Farinae may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a systemic allergic reaction.

• Asthma Status: Patients with asthma are at a higher risk for severe systemic reactions. If a patient is experiencing an asthma flare-up or has significantly reduced lung function (FEV1 < 80% predicted), the dose should be withheld until the asthma is stabilized.
• Oral Inflammation: For SLIT users, treatment should be paused if the patient has oral inflammation (e.g., mouth sores, thrush) or oral surgery/tooth extraction, as this can increase the rate of allergen absorption and the risk of systemic reactions.
• Eosinophilic Esophagitis: Discontinue treatment if the patient develops persistent gastrointestinal symptoms, including dysphagia (difficulty swallowing) or gastroesophageal reflux.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be at higher risk if anaphylaxis occurs, as the physiological stress and the epinephrine used to treat it can strain the heart.

• Initial Observation: 30-minute post-dose monitoring during the first administration.
• Lung Function: Periodic assessment of FEV1 (Forced Expiratory Volume) in patients with a history of asthma.
• Oral Cavity Examination: Regular checks for signs of EoE or severe mucosal irritation.
• Epinephrine Competency: Periodic review of the patient's ability to use an epinephrine auto-injector correctly.

Dermatophagoides Farinae generally does not cause drowsiness or impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been fully evaluated by a medical professional.

There is no direct chemical interaction between alcohol and Dermatophagoides Farinae. However, alcohol consumption can sometimes exacerbate allergic symptoms or mask the early signs of an allergic reaction. It is generally advised to avoid alcohol for a few hours after taking a dose, especially during the build-up phase of SCIT.

If treatment is discontinued for more than a few days, the patient's sensitivity may increase. Do not restart the medication at the previous dose without consulting a physician. Tapering is not usually required for discontinuation, but the 'protective' effect of the immunotherapy will gradually fade if the 3-5 year course is not completed.

> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Dermatophagoides Farinae.

There are no drugs that are strictly 'contraindicated' due to chemical incompatibility; however, certain drugs make the management of side effects dangerously difficult:

• Beta-Blockers (e.g., Propranolol, Metoprolol): These drugs are often used for high blood pressure or heart conditions. They can block the effects of epinephrine. If a patient on beta-blockers has an anaphylactic reaction to Dermatophagoides Farinae, the standard emergency treatment (epinephrine) may not work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These may increase the risk of severe systemic reactions or worsen the drop in blood pressure during an allergic reaction.
• MAO Inhibitors (e.g., Phenelzine) and Tricyclic Antidepressants (e.g., Amitriptyline): These medications can interfere with the metabolism of epinephrine or potentiate its cardiovascular effects, making the treatment of an allergic reaction more complex.

• Other Immunotherapies: If a patient is receiving multiple types of allergy shots (e.g., for grass, mold, and dust mites), the cumulative 'allergic load' is higher, increasing the risk of a systemic reaction. Doses should be spaced out appropriately.
• Corticosteroids: While often used to treat allergies, high doses of systemic steroids might theoretically blunt the immune system's 'learning' response to the immunotherapy, though this is rarely a reason to avoid treatment.

• High-Fat Meals: For SLIT, food should not be in the mouth during administration. There is no evidence that specific foods interact with the extract once absorbed, but patients should avoid eating for 5 minutes post-dose to ensure the proteins have time to interact with the oral mucosa.
• Alcohol: As mentioned, alcohol can increase blood flow to the mucous membranes (vasodilation), potentially increasing the speed of allergen absorption and the risk of a reaction.

• St. John's Wort: No known interaction.
• Immunostimulants (e.g., Echinacea): These may theoretically interfere with the goal of immunotherapy (which is to induce tolerance, not general stimulation), but clinical data is lacking.

• Skin Prick Tests: Dermatophagoides Farinae treatment will eventually cause a decrease in the wheal-and-flare response to dust mite skin tests. This is a sign of efficacy, not a 'false' result.
• Serum IgE/IgG4: Treatment will typically lead to an initial rise in IgE followed by a long-term decrease, and a significant increase in dust-mite-specific IgG4.

For each major interaction, the primary concern is the pharmacodynamic interaction with the emergency treatment (epinephrine) or the additive effect on the immune system's threshold for anaphylaxis.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are on medication for blood pressure, heart rhythm, or depression.

Conditions where Dermatophagoides Farinae must NEVER be used include:

1. 1Severe or Uncontrolled Asthma: Patients with an FEV1 < 80% of predicted value or those with frequent exacerbations are at an unacceptably high risk of a fatal respiratory reaction.
2. 2History of Severe Systemic Allergic Reaction: Anyone who has had a prior life-threatening reaction to any form of dust mite immunotherapy.
3. 3History of Eosinophilic Esophagitis (EoE): Because SLIT can cause or worsen EoE, those with a pre-existing diagnosis should avoid this form of treatment.
4. 4Hypersensitivity to Excipients: Patients allergic to any of the inactive ingredients in the tablet or liquid (such as gelatin or mannitol).

Conditions requiring careful risk-benefit analysis:

• Beta-Blocker Therapy: As noted, this complicates the treatment of anaphylaxis.
• Autoimmune Diseases: There is a theoretical risk that immunotherapy could flare an underlying autoimmune condition (e.g., Lupus, Rheumatoid Arthritis), though evidence is limited.
• Malignancy: Patients with active cancer may have altered immune systems that make immunotherapy less predictable.
• Oral Lesions: Any open wounds in the mouth (e.g., after dental work) are a temporary contraindication to SLIT.

Patients allergic to Dermatophagoides Farinae often show cross-reactivity with Dermatophagoides pteronyssinus (the European house dust mite) due to the similarity of their proteins. There is also documented cross-reactivity with other members of the Pyroglyphidae family and occasionally with shellfish (due to the shared protein tropomyosin). Patients with a severe shellfish allergy should be monitored closely, though they are not strictly contraindicated from dust mite therapy.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Dermatophagoides Farinae.

• FDA Category: Dermatophagoides Farinae is generally considered Category C (under the old system).
• Risk Summary: There are no adequate and well-controlled studies in pregnant women. However, allergen immunotherapy is typically not started during pregnancy because of the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Continuation: If a woman is already on a stable maintenance dose and becomes pregnant, many allergists choose to continue the treatment, as the risk of a reaction is lower during the maintenance phase than during the build-up phase.

It is not known whether Dermatophagoides Farinae allergens are excreted in human milk. Because these are large proteins that are likely digested in the infant's stomach, the risk to the nursing infant is considered very low. The primary concern is the mother's safety and her ability to manage potential reactions while caring for an infant.

• SLIT: Approved for ages 12 and older. Safety and efficacy in children under 12 have not been established for the tablet form in the US.
• SCIT: Often used in children as young as 5. Studies have shown that early intervention with AIT in children can prevent the 'allergic march'—the progression from allergic rhinitis to asthma.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.

Clinical studies of ODACTRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. The main concern in the elderly is the presence of comorbid conditions (like heart disease) that would make a systemic reaction more dangerous.

No studies have been performed in patients with renal impairment. However, since the allergens are proteins that undergo local proteolysis and are not excreted intact by the kidneys, no dose adjustment is anticipated.

No studies have been performed in patients with hepatic impairment. The liver does not play a primary role in the clearance of these allergenic proteins.

> Important: Special populations, particularly pregnant women and those with underlying respiratory disease, require individualized medical assessment and close supervision by an immunology specialist.

Dermatophagoides Farinae extract works by inducing immunological tolerance. The primary targets are the T-lymphocytes and B-lymphocytes.

• T-cell Response: The extract promotes the development of T-regulatory (Treg) cells that secrete IL-10. This suppresses the Th2 response, which is responsible for IgE production and eosinophil recruitment.
• B-cell Response: The extract induces B-cells to switch from producing IgE (the allergy antibody) to IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody. When the patient breathes in dust mite allergens, the IgG4 binds to the allergen first, preventing it from reaching the IgE on the surface of mast cells.

• Dose-Response: Higher doses of the major allergens (Der f 1 and Der f 2) generally lead to a more robust IgG4 response, but also increase the risk of local and systemic reactions.
• Time to Onset: Immunological changes begin within weeks, but clinical improvement typically takes 8 to 14 weeks of daily treatment. Maximum benefit is usually seen after 1 year.
• Duration of Effect: One of the unique aspects of AIT is the 'carry-over' effect. If a patient completes a 3-5 year course, the benefits can last for several years after the treatment is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | Low (systemically); High (locally in oral mucosa) |

| Protein Binding | N/A (Proteins are processed by APCs) |

| Half-life | Minutes to hours (for the proteins themselves) |

| Tmax | Immediate (local contact) |

| Metabolism | Proteolysis by cellular enzymes |

| Excretion | Cellular turnover/metabolic degradation |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from the bodies and fecal pellets of Dermatophagoides farinae mites.
• Major Allergens: Der f 1 (a cysteine protease, ~25 kDa) and Der f 2 (an NPC2 family protein, ~14 kDa).
• Solubility: Highly soluble in aqueous buffered solutions used for injections or sublingual formulations.

Classified as a Standardized Insect Allergenic Extract. It is distinct from non-standardized extracts because its potency is verified against a reference standard, ensuring consistent biological activity across different batches.